Health and medicine news
McGill researchers have discovered the cause of an inherited form of epilepsy. The disease, known as double-cortex syndrome, primarily affects females and arises from mutations on a gene located on the X chromosome. Drs. Susanne Bechstedt and Gary Brouhard of the Dept of Biology have used a highly advanced microscope to discover how these mutations cause a malformation of the human brain.
Mauro Dell’Ambrogio, Swiss Secretary of State for Education and Research, and Ulrich Lehner, Ambassador of Switzerland to Canada and the Bahamas, recently paid a high-profile visit to McGill University. One of their primary goals was to show support for and learn more about the innovative partnership that exists between the Brain@McGill and the Neuroscience Center Zurich.
Cachexia, a syndrome characterized by rapid weight loss and muscle deterioration, is a major cause of death among patients suffering from diseases like cancer, AIDS and chronic infection. Now, a newly published study by McGill University researchers shows that a low dose of Pateamine A is effective at preventing cancer-induced muscle wasting, which may lead to cachexia-fighting drugs.
Whether it is for research into clean energy sources, the future of wireless communication or a better understanding of the processes involved in language learning, over 160 established McGill researchers and more than 80 graduate students will benefit from support from the Natural Sciences and Engineering Research Council of Canada (NSERC) over the next five years.
For anyone to speak out openly and honestly about their struggle with mental illness is an act of bravery. According to a new study of Canadian media coverage of mental illness, journalists rarely quote individuals with mental illness. The study, "Together Against Stigma: Changing how we see mental illness," will be presented Monday at an international conference in Ottawa.
Message from the Office of Sponsored Research and Research Financial Management Services to the McGill Research Community
This communiqué updates the McGill community of some important changes that the Office of Sponsored Research and Research Financial Management Services are undertaking in order to improve our collective services for researchers.
Raptor Pharmaceutical recently announced that it has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of parasitic diseases, including malaria, from McGill.